Cargando…
PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life
[Image: see text] Recombinant urate oxidase (UOX, E.C.1.7.3.3) is an important therapeutic enzyme used in preventing and treating chemotherapy-induced hyperuricemia and severe gout. However, UOX use is limited due to the poor stability and short plasma half-life. To solve this problem, we designed t...
Autores principales: | Najjari, Abbas, Shahbazmohammadi, Hamid, Nojoumi, Seyed Ali, Omidinia, Eskandar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773812/ https://www.ncbi.nlm.nih.gov/pubmed/36570261 http://dx.doi.org/10.1021/acsomega.2c04071 |
Ejemplares similares
-
The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase
por: Najjari, Abbas, et al.
Publicado: (2021) -
Computational Approach for Rational Design of Fusion Uricase with PAS Sequences
por: Najjari, Abbas, et al.
Publicado: (2020) -
PASylation: a biological alternative to PEGylation for extending the
plasma half-life of pharmaceutically active proteins
por: Schlapschy, Martin, et al.
Publicado: (2013) -
Improvement of Certolizumab Fab′ properties by PASylation technology
por: Mazaheri, Somayeh, et al.
Publicado: (2020) -
Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology
por: Aghaabdollahian, Safieh, et al.
Publicado: (2019)